• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

Protalix Biotherapeutics

Monday, June 03, 2024
CP
Cell and Gene Therapy and Genome Editing
Protalix is a biopharmaceutical company focused on the development and commercialization of proprietary recombinant therapeutic proteins expressed through its proprietary ProCellEx® plant cell-based protein expression system. Using ProCellEx, Protalix is developing a pipeline of novel proteins that target large, established pharmaceutical markets and that rely upon known biological mechanisms of action. Our initial commercial focus has been on complex therapeutic proteins, including proteins for the treatment of genetic disorders, such as Gaucher disease and Fabry disease. We believe our ProCellEx protein expression system will enable us to develop proprietary recombinant proteins that are therapeutically equivalent or superior to existing recombinant proteins currently marketed for the same indications. Because we are primarily targeting biologically equivalent versions of highly active, well-tolerated and commercially successful therapeutic proteins.
Protalix Biotherapeutics
Company Website: http://www.protalix.com
Lead Product in Development: PRX-115, PRX-119
Number Of Unlicensed Products (For Which You Are Seeking Partners): 2

Exchange

NYSE, American

Ticker

PLX

Company HQ City

Karmiel

Company HQ State

Israel

Company HQ Country

Israel

CEO/Top Company Official

Dror Bashan

Development Phase of Primary Product

Phase I
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS